PTGER4 promoter methylation is a promising prognostic biomarker for pediatric AML and correlates with improved response to HMAs, and could help refine risk stratification and guide individualized treatment decisions, particularly in patients with baseline thrombocytopenia.
Yu-Juan Xue, Xiao-Yu Cao, Yin-Ping Yang et al.· Frontiers in Pharmacology· 0 citations
Background Wolman disease is the severe infantile form of lysosomal acid lipase deficiency, caused by biallelic pathogenic variants in the Lysosomal Acid Lipase (LIPA) gene. It is rapidly progressive and often fatal within the first year of life without disease-specific therapy. Because early manifestations are non-spe...
Le-Ping Zhang, Qiong Yu, Xinjing Ge et al.· Frontiers in Pediatrics· 0 citations
CD19 CAR-T has achieved high remission rates in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, rapid generation with durable in vivo persistence remains a major challenge. CD45RA-negative T cells exhibit sustained antileukemic activity and preserved immune memory. Here, we developed a rapid p...
Xu-Ying Pei, Meng Lv, Xiao-Zheng Zhao et al.· Cancer Letters· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.